Medicare's recent estimate that the new Alzheimer's treatment Leqembi could cost the program $3.5 billion in 2025 has sparked significant discussion, highlighting a discrepancy with Wall Street and the drug manufacturer's projections, being several times what was expected. This comes as the first drug shown to slow Alzheimer's disease faces a slow start in the U.S. market, with lagging sales, delayed adoption by major hospital systems, and some insurers rejecting coverage. Additionally, concerns are raised about Medicare spending $3.5 billion on Leqembi, labeled as a proven ineffective drug, while not covering anti-obesity meds with far superior data for positive health outcomes.
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. https://t.co/hJknxe0Uvq
It’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start? https://t.co/uf7vq1dRzr
It’s the First Drug Shown to Slow Alzheimer’s. Why Is Is It Off to a Slow Start? https://t.co/MZXAYrjmqM
The first drug shown to slow Alzheimer's disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. https://t.co/ng9FLGu1Mo
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start? https://t.co/Zyzifr9VWo https://t.co/5Eiax9ham8
New STAT exclusive: The Alzheimer’s treatment Leqembi could cost the entire Medicare program $3.5 billion in 2025, according to a document obtained by @bobjherman and @rachelcohrs. https://t.co/Fy6SwGhpQz
Medicare expects to spend $3.5 bln on a proven ineffective drug but will not cover anti-obesity meds with far superior data for positive health outcomes. Should we start calling obesity type 2 Alzheimer’s for better drug coverage? https://t.co/NST90LYBLb
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project. https://t.co/tABirskpYT
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond what Wall Street or even the drug’s manufacturer has projected — according to a document obtained by STAT. https://t.co/GEdAMvJ8XI
Medicare expects to spend $3.5 billion on the Alzheimer's treatment Leqembi in 2025 — well beyond what Wall Street or even the drug's manufacturer has projected. Read more from @rachelcohrs and me: https://t.co/ms8E2ekU8p
Medicare expects to spend $3.5 billion on the Alzheimer's treatment Leqembi in 2025 — well beyond what Wall Street or even the drug’s manufacturer has projected. Read more from @rachelcohrs and me: https://t.co/ms8E2ekU8p
Medicare estimates that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond what Wall Street projects. https://t.co/KNL0GtW96Y
This is weird. Medicare estimates $3.5 billion cost on Alzheimer's drug Leqembi. Which is several times what Wall Street and the company expect. By @bobjherman and @rachelcohrs. (Personally I would bet on a lower number here…) https://t.co/Ca8WoEEdaG
A Miami biotech developing a drug to treat Alzheimer's disease is cutting back on some research and development. Here's why. https://t.co/T0kUsxqxh4